DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0116468 A1 RYU Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0116468 A1 RYU Et Al US 201601 16468A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0116468 A1 RYU et al. (43) Pub. Date: Apr. 28, 2016 (54) METHOD OF ANALYZING BINDING ASPECT Publication Classification OF MEMBRANE PROTEIN IN A LIVING CELL (51) Int. Cl. GOIN 33/557 (2006.01) (71) Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION, Gyeongsangbuk-do (52) U.S. Cl. (KR) CPC .................................... G0IN33/557 (2013.01) (72) Inventors: Sung Ho RYU, Gyeongsangbuk-do (KR); Dohyeon KIM, Seoul (KR): Nam (57) ABSTRACT Ki LEE, Gyeongsangbuk-do (KR); Dong Kyun KIM, Gyeongsangbuk-do (KR); Soyeon PARK, Seoul (KR): The present invention relates to a method for analyzing the Yonghoon KWON, Seoul (KR): Kai pattern of live intercellular membrane protein binding. The ZHOU, Gyeongsangbuk-do (KR) method for analyzing the pattern according to the present (21) Appl. No.: 14/891,555 invention can analyze accurately, sensitively, quickly, and readily the binding pattern of a target membrane protein and (22) PCT Fled: May 16, 2014 a candidate substance to be specifically bound therewith with (86) PCT NO.: PCTAKR2014/004.426 out tagging to a ligand, and thus measure directly and accu rately the position and quantitative information of the binding S371 (c)(1), (2) Date: Nov. 16, 2015 of the membrane protein and the target Substance. Such effects make it possible to apply the method for various uses (30) Foreign Application Priority Data Such as dissociation constant, mutant study, complex forma tion, and signal transduction. Moreover, it is expected to use May 16, 2013 (KR) ........................ 10-2013-OO56008 Nov. 29, 2013 (KR) ................. PCTAKR2O13/O110O2 the method for searching out undiscovered membrane pro May 16, 2014 (KR) ........................ 10-2014-OO59.027 teins and target substances. Patent Application Publication Apr. 28, 2016 Sheet 1 of 19 US 2016/0116468 A1 FIG. 1 extraceuiar intfacetia rtation tita RYA : refectic light intraceluiar tipid bilayer igand tein) are 3rotei it joiescert proteir FIG. 2 tle growth is 888 & .. dow condition stipe Safia ercia a tice &yeage aiyef age taking cS is a A. SS s refection microscope R & (ojective less {&rctic in 2 time (cycie Patent Application Publication Apr. 28, 2016 Sheet 2 of 19 US 2016/0116468 A1 FIG. 3 Cetuximab xii) Patent Application Publication Apr. 28, 2016 Sheet 3 of 19 US 2016/0116468 A1 FIG. 4 pMT NT PVT. Cetuximab 1.0 . 8. s ( Cy FIG.S. exist a a. O 2 O O PM EGFR Patent Application Publication Apr. 28, 2016 Sheet 4 of 19 US 2016/0116468 A1 FIG. 6) heterotrimeric Gi potei AOP ribosylated Gigotei & Petassis oxii i-S Fzb, Wy FIG. 7 SS OO TX SO 40 2 -2 O -- PMT FZD1 B2-AR Patent Application Publication Apr. 28, 2016 Sheet 5 of 19 US 2016/0116468 A1 FIG. 8 ()meie, FIG.9) ax batch at C2 at C3- at C3-2 different batches reasi?ed of the Sane day Patent Application Publication Apr. 28, 2016 Sheet 6 of 19 US 2016/0116468 A1 FIG. 10 a - -ex.283 (el b- irie 3 ce. & & ... , 58 SO S. g 4{ 2 40 S. is 30 g 20a g 20. 10 10 S s s: 3 ice. o N. -- g ;: EGR g $ 83-8 C CO-K Ce: d as so S.se 50 s s 40. 40 s 5 20 ; 20 s s . ... g oil , a lic YYYY YY YY s i -EKS3 i88 Chi-X s ce ce {& FIG. 11 A R Patent Application Publication Apr. 28, 2016 Sheet 7 of 19 US 2016/0116468 A1 FIG. 12 pEGFR (Y1086 EGFR FIG. 13 S O 4. O 2 O is S T Patent Application Publication Apr. 28, 2016 Sheet 8 of 19 US 2016/0116468 A1 FIG. 14) - fluorescent protein FIG. 15 . S (arbitrary unit) Patent Application Publication Apr. 28, 2016 Sheet 9 of 19 US 2016/0116468 A1 FIG.16 50 PMT EGFR 2 5 O texifraix tasizia acti artiady FIG. 17 Ceituxina Fata cetixifra Fab againe: Patent Application Publication Apr. 28, 2016 Sheet 10 of 19 US 2016/0116468 A1 FIG. 18) EGFR 5 e aaf{f C&tuxia (exifra Cei Xia Fa a2 O 40 8O 12O 16O molecular weight (kilodalton) Patent Application Publication Apr. 28, 2016 Sheet 11 of 19 US 2016/0116468 A1 FIG. 20 Patent Application Publication Apr. 28, 2016 Sheet 12 of 19 US 2016/0116468 A1 FIG. 21 O.02 (ugimitreated cetuximab concentration 1.0 - -2 O.8 is first measurement is second reasurement O6 treatment time point Patent Application Publication Apr. 28, 2016 Sheet 13 of 19 US 2016/0116468 A1 FIG.22) dissociatio constant Ks is 0.8 . , 8 y & s s^s / ^ 8s a S. c. 0.5 8 Sf :: s: . werg 5 S S haa 3 . i. 8 12 ratic Ceix Sat-3rd GR rt also 2 & 8 O.8 8 Cettixinhab girl FIG. 23) stry frutant Str WT (wild type) Patent Application Publication Apr. 28, 2016 Sheet 14 of 19 US 2016/0116468 A1 FIG. 24 S. Cettixia S A R 3. s FIG. 25 s s O 5 o2 os os os to (, 3i Oi city&isian-Si 3FRy: olo oa o os os o 12 4 cetuximab (ign) Patent Application Publication Apr. 28, 2016 Sheet 15 of 19 US 2016/0116468 A1 FIG. 26) cetaxia t secondary artibody t tertiary antibody FIG. 27 , treatinent point x: 8. te rt iary antibody 5 . ^ Ns 10 2 3. time (minute) Patent Application Publication Apr. 28, 2016 Sheet 16 of 19 US 2016/0116468 A1 FIG. 28 in treating point O O & tertiary antibody W) 0.75 & O.50 O O 2O 3O time (minute) FIG. 29) & fief:S SR &ftistiy Alexa of 64 Patent Application Publication Apr. 28, 2016 Sheet 17 of 19 US 2016/0116468 A1 FIG. 30 five-fescetice tail { ai: Cities: 8 is is: me a 38 fig to Céxi &i gigi) fii (fessi: (.. : . & A is is, 3 + £&iaxina (Exigiri) * ...etixis via {}{igin: f8: i. R r | 88 it (3 & $ 3 of: forescence ritersity ofescence intersity (arbitrary unit) (arbitsary unit FIG. 31 5 ...) 4. - 3. 2 Patent Application Publication Apr. 28, 2016 Sheet 18 of 19 US 2016/0116468 A1 FIG. 32 S is turboglobulin a tibody x CetuXiao . 2 {. COS A43 MA-M8-23 BT20 CC8 Ce ce Ce Cei Ce FIG.33) Patent Application Publication Apr. 28, 2016 Sheet 19 of 19 US 2016/0116468 A1 FIG. 34 50 Cetuximab treatment 4. O 3 O 2 O 1 O O BASC endothelial AT2 Clara Cei cel ce US 2016/0116468 A1 Apr. 28, 2016 METHOD OF ANALYZING BINDING ASPECT the candidate material in a living cell expressing the target OF MEMBRANE PROTEIN IN A LIVING membrane protein; and analyzing a change in diffusion coef CELL ficient of at least one target membrane protein obtained thereby. TECHNICAL FIELD 0008 Also, in another aspect, another exemplary embodi 0001. The present invention relates to a method of analyz ment of the present invention provides a method of screening ing a binding aspect between a membrane protein and a a drug for a target membrane protein, the method including: candidate material in a living cell. analyzing a binding aspect between a candidate material and a target membrane protein; and determining a drug specifi BACKGROUND ART cally acting on the target membrane protein among the can didate materials using the binding aspect. 0002. A cell membrane is an essential factor for maintain ing a cell, and membrane proteins localized in the cell mem 0009. Hereinafter, the present invention will be described brane play an important role in intracellular and extracellular in detail. communication through dynamic interaction with ligands. 0010. The present invention provides a method of analyz Substantially, about a half of cellular proteins are known to be ing a binding aspect between a candidate material and a target able to interact with ligands in the cell membrane, but huge membrane protein, the method including: measuring a diffu parts still remain unknown. To figure out such interactions, a sion coefficient of the target membrane protein before and variety of techniques and attempts have been conducted over after the candidate material is treated in a living cell express the years, and researchers are still making efforts. ing the target membrane protein; and analyzing a change in 0003. Since an extracellular environment has a relatively diffusion coefficient of at least one target membrane protein very small viscosity, compared to an inside of the cell mem obtained thereby. brane, the influence of an extracellular domain of the mem 0011 A variety of dynamic interaction between mem brane protein which directly binds to ligands on the diffusiv brane proteins and ligands is one of the cellular responses to ity of target proteins has been ignored, and many researches various environmental changes. A complex of the membrane relating to the diffusion theory of membrane proteins, which protein bound with various ligands serves in various roles. is the Saffman-Delbruck model, focus on a transmembrane However, since the identification of such a membrane protein domain to determine such diffusivity of the membrane pro complex is technically limited, much of the complex is still teins and describe its importance on membrane protein dif unknown. To overcome Such a limitation, the inventors com fusion. Therefore, it has been considered that it is fundamen pleted a single molecule diffusional motion shift assay (sm tally difficult to measure the binding of ligands to the DIMSA) in which single particle tracking (SPT) combined extracellular domain of the target membrane proteinbased on with Super-resolution microscopy is utilized, and this method diffusion of membrane protein. However, since a system used can be applied as a method of analyzing a binding aspect in the conventional research could measure the interaction between a candidate material and a target membrane protein.
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • Dissecting Signaling and Functions of Adhesion G Proteincoupled Receptors
    Ann. N.Y. Acad. Sci. ISSN 0077-8923 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Issue: Annals Meeting Reports Dissecting signaling and functions of adhesion G protein–coupled receptors Demet Arac¸,1 Gabriela Aust,2 Davide Calebiro,3 Felix B. Engel,4 Caroline Formstone,5 Andre´ Goffinet,6 Jorg¨ Hamann,7 Robert J. Kittel,8 Ines Liebscher,9 Hsi-Hsien Lin,10 Kelly R. Monk,11 Alexander Petrenko,12 Xianhua Piao,13 Simone Promel,¨ 9 HelgiB.Schioth,¨ 14 Thue W. Schwartz,15 Martin Stacey,16 Yuri A. Ushkaryov,17 Manja Wobus,18 Uwe Wolfrum,19 Lei Xu,20 and Tobias Langenhan8 1Stanford University, Stanford, California. 2Department of Surgery, Research Laboratories, University of Leipzig, Leipzig, Germany. 3Institute of Pharmacology and Rudolf Virchow Center, DFG-Research Center for Experimental Biomedicine, University of Wurzburg,¨ Wurzburg,¨ Germany. 4Department of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany, and Laboratory of Experimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, University of Erlangen-Nurnberg,¨ Erlangen, Germany. 5MRC Centre for Developmental Neurobiology, King’s College London, New Hunts House, London, United Kingdom. 6Universite´ Catholique de Louvain, Institute of Neuroscience, Developmental Neurobiology, Brussels, Belgium. 7Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 8Institute of Physiology, Department of Neurophysiology, University of Wurzburg,¨ Wurzburg,¨ Germany. 9Institute of Biochemistry, Molecular Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany. 10Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan. 11Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri. 12Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
    [Show full text]
  • Cognition and Steroidogenesis in the Rhesus Macaque
    Cognition and Steroidogenesis in the Rhesus Macaque Krystina G Sorwell A DISSERTATION Presented to the Department of Behavioral Neuroscience and the Oregon Health & Science University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2013 School of Medicine Oregon Health & Science University CERTIFICATE OF APPROVAL This is to certify that the PhD dissertation of Krystina Gerette Sorwell has been approved Henryk Urbanski Mentor/Advisor Steven Kohama Member Kathleen Grant Member Cynthia Bethea Member Deb Finn Member 1 For Lily 2 TABLE OF CONTENTS Acknowledgments ......................................................................................................................................................... 4 List of Figures and Tables ............................................................................................................................................. 7 List of Abbreviations ................................................................................................................................................... 10 Abstract........................................................................................................................................................................ 13 Introduction ................................................................................................................................................................. 15 Part A: Central steroidogenesis and cognition ............................................................................................................
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Supplementary Data
    Supplemental Data A novel mouse model of X-linked nephrogenic diabetes insipidus: Phenotypic analysis and therapeutic implications Jian Hua Li, Chung-Lin Chou, Bo Li, Oksana Gavrilova, Christoph Eisner, Jürgen Schnermann, Stasia A. Anderson, Chu-Xia Deng, Mark A. Knepper, and Jürgen Wess Supplemental Methods Metabolic cage studies. Animals were maintained in mouse metabolic cages (Hatteras Instruments, Cary, NC) under controlled temperature and light conditions (12 hr light and dark cycles). Mice received a fixed daily ration of 6.5 g of gelled diet per 20 g of body weight per day. The gelled diet was composed of 4 g of Basal Diet 5755 (Test Diet, Richmond, IN), 2.5 ml of deionized water, and 65 mg agar. Preweighted drinking water was provided ad libitum during the course of the study. Mice were acclimated in the metabolic cages for 1-2 days. Urine was collected under mineral oil in preweighted collection vials for successive 24 hr periods. Analysis of GPCR expression in mouse IMCD cells via TaqMan real-time qRT-PCR. Total RNA prepared from mouse IMCD tubule suspensions was reverse transcribed as described under Experimental Procedures. Tissues from ten 10-week old C57BL/6 WT mice were collected and pooled for each individual experiment. cDNA derived from 640 ng of RNA was mixed with an equal volume of TaqMan gene expression 2 x master mix (Applied Biosystems, Foster City, CA). 100 μl-aliquots of this mixture (corresponding to 80 ng of RNA) were added to each of the 8 fill ports of a 384-well plate of a mouse GPCR array panel (Applied Biosystems).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Targeting Lysophosphatidic Acid in Cancer: the Issues in Moving from Bench to Bedside
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks cancers Review Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside Yan Xu Department of Obstetrics and Gynecology, Indiana University School of Medicine, 950 W. Walnut Street R2-E380, Indianapolis, IN 46202, USA; [email protected]; Tel.: +1-317-274-3972 Received: 28 August 2019; Accepted: 8 October 2019; Published: 10 October 2019 Abstract: Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications. Keywords: Autotaxin (ATX); ovarian cancer (OC); cancer stem cell (CSC); electrospray ionization tandem mass spectrometry (ESI-MS/MS); G-protein coupled receptor (GPCR); lipid phosphate phosphatase enzymes (LPPs); lysophosphatidic acid (LPA); phospholipase A2 enzymes (PLA2s); nuclear receptor peroxisome proliferator-activated receptor (PPAR); sphingosine-1 phosphate (S1P) 1.
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • ADGRE1 (EMR1, F4/80) Is a Rapidly-Evolving Gene Expressed In
    Edinburgh Research Explorer ADGRE1 (EMR1, F4/80) Is a Rapidly-Evolving Gene Expressed in Mammalian Monocyte-Macrophages Citation for published version: Waddell, L, Lefevre, L, Bush, S, Raper, A, Young, R, Lisowski, Z, McCulloch, M, Muriuki, C, Sauter, K, Clark, E, Irvine, KN, Pridans, C, Hope, J & Hume, D 2018, 'ADGRE1 (EMR1, F4/80) Is a Rapidly-Evolving Gene Expressed in Mammalian Monocyte-Macrophages' Frontiers in Immunology, vol. 9, 2246. DOI: 10.3389/fimmu.2018.02246 Digital Object Identifier (DOI): 10.3389/fimmu.2018.02246 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Frontiers in Immunology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 05. Apr. 2019 ORIGINAL RESEARCH published: 01 October 2018 doi: 10.3389/fimmu.2018.02246 ADGRE1 (EMR1, F4/80) Is a Rapidly-Evolving Gene Expressed in Mammalian Monocyte-Macrophages Lindsey A. Waddell 1†, Lucas Lefevre 1†, Stephen J. Bush 2†, Anna Raper 1, Rachel Young 1, Zofia M.
    [Show full text]
  • Technical Note, Appendix: an Analysis of Blood Processing Methods to Prepare Samples for Genechip® Expression Profiling (Pdf, 1
    Appendix 1: Signature genes for different blood cell types. Blood Cell Type Source Probe Set Description Symbol Blood Cell Type Source Probe Set Description Symbol Fraction ID Fraction ID Mono- Lympho- GSK 203547_at CD4 antigen (p55) CD4 Whitney et al. 209813_x_at T cell receptor TRG nuclear cytes gamma locus cells Whitney et al. 209995_s_at T-cell leukemia/ TCL1A Whitney et al. 203104_at colony stimulating CSF1R lymphoma 1A factor 1 receptor, Whitney et al. 210164_at granzyme B GZMB formerly McDonough (granzyme 2, feline sarcoma viral cytotoxic T-lymphocyte- (v-fms) oncogene associated serine homolog esterase 1) Whitney et al. 203290_at major histocompatibility HLA-DQA1 Whitney et al. 210321_at similar to granzyme B CTLA1 complex, class II, (granzyme 2, cytotoxic DQ alpha 1 T-lymphocyte-associated Whitney et al. 203413_at NEL-like 2 (chicken) NELL2 serine esterase 1) Whitney et al. 203828_s_at natural killer cell NK4 (H. sapiens) transcript 4 Whitney et al. 212827_at immunoglobulin heavy IGHM Whitney et al. 203932_at major histocompatibility HLA-DMB constant mu complex, class II, Whitney et al. 212998_x_at major histocompatibility HLA-DQB1 DM beta complex, class II, Whitney et al. 204655_at chemokine (C-C motif) CCL5 DQ beta 1 ligand 5 Whitney et al. 212999_x_at major histocompatibility HLA-DQB Whitney et al. 204661_at CDW52 antigen CDW52 complex, class II, (CAMPATH-1 antigen) DQ beta 1 Whitney et al. 205049_s_at CD79A antigen CD79A Whitney et al. 213193_x_at T cell receptor beta locus TRB (immunoglobulin- Whitney et al. 213425_at Homo sapiens cDNA associated alpha) FLJ11441 fis, clone Whitney et al. 205291_at interleukin 2 receptor, IL2RB HEMBA1001323, beta mRNA sequence Whitney et al.
    [Show full text]
  • Genetic Evidence That Celsr3 and Celsr2, Together with Fzd3, Regulate Forebrain Wiring in a Vangl-Independent Manner
    Genetic evidence that Celsr3 and Celsr2, together with Fzd3, regulate forebrain wiring in a Vangl-independent manner Yibo Qua, Yuhua Huanga, Jia Fenga, Gonzalo Alvarez-Boladob, Elizabeth A. Grovec, Yingzi Yangd, Fadel Tissire, Libing Zhoua,f,1,2, and Andre M. Goffinete,1,2 aGuangdong–Hong Kong–Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China; bDepartment of Neuroanatomy, Heidelberg University, D-69120 Heidelberg, Germany; cNeuroscience, The University of Chicago, Chicago, IL 60637; dNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; eWELBIO - Walloon Excellence in Life Sciences and Biotechnology and Institute of Neuroscience, University of Louvain, B1200 Brussels, Belgium; and fState Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong Edited* by Jeremy Nathans, The Johns Hopkins University, Baltimore, MD, and approved June 18, 2014 (received for review February 3, 2014) Celsr3 and Fzd3, members of “core planar cell polarity” (PCP) AC contains commissural axons from the anterior olfactory nu- genes, were shown previously to control forebrain axon guidance clei and from the temporal cortex, which cross the midline at and wiring by acting in axons and/or guidepost cells. Here, we embryonic day 13.5 (E13.5) to E14.5 (11–14). The IC contains show that Celsr2 acts redundantly with Celsr3, and that their com- three main axonal components. Thalamocortical axons (TCA) bined mutation mimics that of Fzd3. The phenotypes generated emerge from the thalamus—formerly called “dorsal” thalamus upon inactivation of Fzd3 in different forebrain compartments are (15)—at E12.5. They run through the prethalamus (former similar to those in conditional Celsr2-3 mutants, indicating that “ventral” thalamus), turn and cross the diencephalon–telen- Fzd3 and Celsr2-3 act in the same population of cells.
    [Show full text]
  • G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes
    Int. J. Mol. Sci. 2014, 15, 1112-1142; doi:10.3390/ijms15011112 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review G Protein-Coupled Receptors: What a Difference a ‘Partner’ Makes Benoît T. Roux 1 and Graeme S. Cottrell 2,* 1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK; E-Mail: [email protected] 2 Reading School of Pharmacy, University of Reading, Reading RG6 6UB, UK * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-118-378-7027; Fax: +44-118-378-4703. Received: 4 December 2013; in revised form: 20 December 2013 / Accepted: 8 January 2014 / Published: 16 January 2014 Abstract: G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately, mutations and dysregulation of GPCRs that induce a loss of function or alter expression can lead to disorders that are sometimes lethal. Therefore, the expression, trafficking, signaling and desensitization of GPCRs must be tightly regulated by different cellular systems to prevent disease. Although there is substantial knowledge regarding the mechanisms that regulate the desensitization and down-regulation of GPCRs, less is known about the mechanisms that regulate the trafficking and cell-surface expression of newly synthesized GPCRs. More recently, there is accumulating evidence that suggests certain GPCRs are able to interact with specific proteins that can completely change their fate and function. These interactions add on another level of regulation and flexibility between different tissue/cell-types.
    [Show full text]